Skip to content
Review Open access

Beyond target presence: A cross-cancer contextual framework for siRNA therapeutics in solid tumors.

Oct 2026 · Biochimica et biophysica acta. Reviews on cancer · Vol 1881, pp. 189732 · 0 citations · 141 references
Medicine

TL;DR

This review compares non-small cell lung cancer, pancreatic ductal adenocarcinoma, breast cancer, glioblastoma, and hepatocellular carcinoma across four interconnected dimensions: resistance networks, tumor microenvironmental reprogramming, metastatic progression, and delivery-system design.

Abstract

Small interfering RNA (siRNA) has achieved clinical success in liver-directed therapies, but its translation to solid tumors remains limited by heterogeneous delivery and context-dependent target dependence. This review compares non-small cell lung cancer, pancreatic ductal adenocarcinoma, breast cancer, glioblastoma, and hepatocellular carcinoma across four interconnected dimensions: resistance networks, tumor microenvironmental reprogramming, metastatic progression, and delivery-system design. We examine how bypass signaling and phenotypic plasticity influence target selection, how stromal and immune compartments shape therapeutic responses, and how disease stage and organ-specific barriers alter delivery requirements. We then assess representative clinical RNA interference programs to distinguish evidence of tissue exposure and target engagement from antitumor activity and established clinical benefit. Across these settings, tumor accumulation does not establish productive cytosolic delivery, and target knockdown alone does not ensure durable disease control. We propose a context-dependent framework that aligns functional target dependence with the intended cell population, tissue environment, treatment timing, and delivery route. Priorities include resistance-informed combinations, prospective validation of delivery biomarkers, repeat-dose safety assessment, and carrier designs whose functional benefits justify their manufacturing complexity. By linking mechanistic comparison with clinical evidence, this review identifies testable criteria for selecting patients, evaluating functional delivery, and advancing siRNA therapeutics for solid tumors.

Read PDF

Similar papers

#gene editing Review Open access Oct 2026

From Target Discovery to Spatial Delivery: A Translational Roadmap for Gene-Targeted Therapies in Glioma

This review connects target discovery to clinical development by integrating spatial and longitudinal tumor biology with payload selection, delivery engineering, biomarker design, manufacturing, and mechanism-driven trials, and argues that the clinically actionable unit in diffuse glioma is often a target-anatomical co...

Hao Cheng, Ying-Chao Zhang, Jin-Bo Zhu et al. · 0 citations
Review Sep 2026

Nanocarrier-Mediated Nucleic Acid Therapy in Non-Small Cell Lung Cancer: Converging Delivery Barriers, Resistance Reversal, and Clinical Translation.

Future nanocarrier-based gene therapy for NSCLC should move beyond material innovation toward barrier-informed, resistance-matched, biomarker-guided, and clinically scalable precision nanomedicine.

Hai-Tao Yu, Jian-Qin Yan, Song Gao et al. · 0 citations
Review Open access Oct 2026

Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions

Metastatic cancer remains a major clinical challenge, which is driven by the continuous adaptation of disseminated tumor cells to diverse tissue environments and therapeutic pressures. Although current treatments, including conventional therapies, small-molecule drugs, antibody-drug conjugates, and immunotherapies, hav...

H. Ye, Yu-Quan Wei, Xue-Mei He et al. · 0 citations
Review Open access Oct 2026

Overcoming adaptive resistance in non-small cell lung cancer: integrating targeted therapies, immunotherapy synergy, and nanocarrier delivery

Lung cancer is the leading cause of cancer death, characterized by high mortality rates, tumor adaptation and heterogeneity, and immune evasion mechanisms. Despite recent advancements in chemotherapy, radiation, and surgery, survival rates for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) remain...

Lu-Ke Ding, Anna Staśkiewicz, Jesse Kao et al. · 0 citations
Review Open access Oct 2026

Translational Challenges and Strategies for Antibody Therapeutics in Glioblastoma

Glioblastoma (GBM) remains difficult to control. Monoclonal antibodies (mAbs) have transformed the treatment of several extracranial cancers, but they have not consistently improved survival in GBM. This narrative review examines the main biological and translational barriers to antibody-based therapy. It also evaluate...

Yang Zhou, You-Ming Li, Yu Chen et al. · 0 citations
Review Open access Sep 2026

Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer

Abstract Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype, and its poor prognosis, chemoresistance, and limited immunotherapy response are closely linked to pathological remodeling of the tumor microenvironment (TME). Targeting the TME has emerged as a promising strategy, but convention...

Yong-Xuan Long, Hong-Yu Yin, Jin-Bo Li et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.